CytomX Therapeutics' (CTMX) "Outperform" Rating Reiterated at Wedbush

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report)'s stock had its "outperform" rating reiterated by analysts at Wedbush in a research report issued to clients and investors on Friday,RTT News reports. They presently have a $5.00 target price on the biotechnology company's stock.

Separately, HC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, CytomX Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $5.02.

CytomX Therapeutics Stock Down 7.4 %

NASDAQ:CTMX traded down $0.05 during mid-day trading on Friday, hitting $0.62. 1,989,577 shares of the company traded hands, compared to its average volume of 2,620,852. The stock's fifty day moving average price is $0.83 and its 200-day moving average price is $1.01. The firm has a market cap of $48.55 million, a price-to-earnings ratio of 3.65 and a beta of 1.05. CytomX Therapeutics has a one year low of $0.60 and a one year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.45. The firm had revenue of $38.09 million for the quarter, compared to analysts' expectations of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Equities analysts predict that CytomX Therapeutics will post -0.05 EPS for the current year.

Remove Ads

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Miller Financial Services LLC purchased a new position in CytomX Therapeutics during the fourth quarter valued at $26,000. Traphagen Investment Advisors LLC purchased a new position in shares of CytomX Therapeutics during the fourth quarter valued at about $31,000. Algert Global LLC bought a new stake in shares of CytomX Therapeutics in the fourth quarter worth about $35,000. Velan Capital Investment Management LP bought a new stake in shares of CytomX Therapeutics in the fourth quarter worth about $36,000. Finally, US Bancorp DE purchased a new stake in shares of CytomX Therapeutics in the third quarter worth about $40,000. Institutional investors own 67.77% of the company's stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.